Is a
Product attributes
Product Parent Company
DALIRESP® (roflumilast) is indicated as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Limitations of Use
- DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm
- DALIRESP 250 mcg is a starting dose for the first 4 weeks of treatment only and is not the effective (therapeutic) dose
Please read full Prescribing Information, including Medication Guide.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
